These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 11821946)
1. Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway. Nam SY; Amoscato AA; Lee YJ Oncogene; 2002 Jan; 21(3):337-46. PubMed ID: 11821946 [TBL] [Abstract][Full Text] [Related]
2. Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathway. Kim KM; Lee YJ Oncogene; 2005 Jan; 24(3):355-66. PubMed ID: 15558024 [TBL] [Abstract][Full Text] [Related]
3. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Asakuma J; Sumitomo M; Asano T; Asano T; Hayakawa M Cancer Res; 2003 Mar; 63(6):1365-70. PubMed ID: 12649200 [TBL] [Abstract][Full Text] [Related]
4. Time sequence of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin treatment is responsible for a complex pattern of synergistic cytotoxicity. Kim YH; Lee YJ J Cell Biochem; 2006 Aug; 98(5):1284-95. PubMed ID: 16514644 [TBL] [Abstract][Full Text] [Related]
5. eNOS protects prostate cancer cells from TRAIL-induced apoptosis. Tong X; Li H Cancer Lett; 2004 Jul; 210(1):63-71. PubMed ID: 15172122 [TBL] [Abstract][Full Text] [Related]
6. TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation. Kim YH; Lee YJ J Cell Biochem; 2007 Mar; 100(4):998-1009. PubMed ID: 17031854 [TBL] [Abstract][Full Text] [Related]
8. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Ozören N; El-Deiry WS Neoplasia; 2002; 4(6):551-7. PubMed ID: 12407450 [TBL] [Abstract][Full Text] [Related]
9. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Mitsiades N; Poulaki V; Mitsiades C; Tsokos M Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151 [TBL] [Abstract][Full Text] [Related]
10. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells. Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850 [TBL] [Abstract][Full Text] [Related]
11. Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis. Kim JH; Ajaz M; Lokshin A; Lee YJ Clin Cancer Res; 2003 Aug; 9(8):3134-41. PubMed ID: 12912965 [TBL] [Abstract][Full Text] [Related]
12. ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation. Suzuki A; Kusakai G; Kishimoto A; Lu J; Ogura T; Esumi H Oncogene; 2003 Sep; 22(40):6177-82. PubMed ID: 13679856 [TBL] [Abstract][Full Text] [Related]
13. Amiloride potentiates TRAIL-induced tumor cell apoptosis by intracellular acidification-dependent Akt inactivation. Cho YL; Lee KS; Lee SJ; Namkoong S; Kim YM; Lee H; Ha KS; Han JA; Kwon YG; Kim YM Biochem Biophys Res Commun; 2005 Jan; 326(4):752-8. PubMed ID: 15607733 [TBL] [Abstract][Full Text] [Related]
14. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors. Aggarwal BB; Bhardwaj U; Takada Y Vitam Horm; 2004; 67():453-83. PubMed ID: 15110190 [TBL] [Abstract][Full Text] [Related]
15. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419 [TBL] [Abstract][Full Text] [Related]
16. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Sun SY; Yue P; Hong WK; Lotan R Cancer Res; 2000 Dec; 60(24):7149-55. PubMed ID: 11156424 [TBL] [Abstract][Full Text] [Related]
17. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Ravi R; Bedi A Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014 [TBL] [Abstract][Full Text] [Related]
18. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. Kang J; Bu J; Hao Y; Chen F Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917 [TBL] [Abstract][Full Text] [Related]
19. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. Fulda S; Meyer E; Debatin KM Cancer Res; 2000 Jul; 60(14):3947-56. PubMed ID: 10919673 [TBL] [Abstract][Full Text] [Related]
20. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Ozoren N; Kim K; Burns TF; Dicker DT; Moscioni AD; El-Deiry WS Cancer Res; 2000 Nov; 60(22):6259-65. PubMed ID: 11103780 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]